Medication Adherence Among Patients with Advanced Prostate Cancer Using Oral Therapies
Dominic Pilon, Joyce LaMori, Carmine Rossi, Mike Durkin, Isabelle Ghelerter, Xuehua Ke, Marie‐Hélène Lafeuille, Lorie Ellis, Patrick Lefèbvre
Abstract
Aims: In light of the extended overall survival and improved quality of life provided by advanced prostate cancer (PC) oral therapies, this study aimed to describe treatment adherence to advanced PC oral therapies and evaluate associated patient characteristics and subsequent healthcare resource utilization (HRU). Patients & methods: Patients with advanced PC initiating apalutamide, enzalutamide or abiraterone acetate were identified from administrative data (October 1, 2014–September 30, 2019). Adherence and persistence at six months postinitiation were used to evaluate patient factors and HRU. Results: Aged ≥75 years, Black race, chemotherapy use and higher pharmacy paid amounts were associated with poor adherence/persistence, which translated to higher HRU. Conclusions: Strategies to increase adherence and persistence may improve patient outcomes and associated HRU.